Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:THRX
- CUSIP: N/A
- Web: www.inva.com/
- 50 Day Moving Avg: $9.81
- 200 Day Moving Avg: $11.67
- 52 Week Range: $6.36 - $21.16
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 32.70
- P/E Growth: 0.00
- Net Margins: 60.02%
- Return on Assets: 36.91%
- Average Volume: 867,484 shs.
Frequently Asked Questions for Innoviva (NASDAQ:THRX)
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "THRX."
Who are some of Innoviva's key competitors?
Some companies that are related to Innoviva include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis AG (NVS), Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY) and Patheon NV (PTHN).
Who are Innoviva's key executives?
Innoviva's management team includes the folowing people:
- William H. Waltrip, Independent Chairman of the Board
- Eric D'Esparbes, Chief Financial Officer, Senior Vice President
- Theodore J. Witek Jr., Senior Vice President, Chief Scientific Officer
- Michael E. Faerm, Senior Vice President and Chief Business Officer
- Michael W. Aguiar, President, Chief Executive Officer, Director
- Barbara G. Duncan, Independent Director
- Catherine J. Friedman, Independent Director
- Patrick G. LePore, Independent Director
- Paul A. Pepe, Independent Director
How do I buy Innoviva stock?
Shares of Innoviva can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innoviva's stock price today?
MarketBeat Community Rating for Innoviva (NASDAQ THRX)MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Innoviva stock can currently be purchased for approximately $9.81.
Consensus Ratings for Innoviva (NASDAQ:THRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Innoviva (NASDAQ:THRX)
(Data available from 9/20/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/2/2016||Morgan Stanley||Reiterated Rating||Sell||$7.00||N/A|
Earnings History for Innoviva (NASDAQ:THRX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Innoviva (NASDAQ:THRX)
Current Year EPS Consensus Estimate: $-0.19 EPS
Next Year EPS Consensus Estimate: $0.30 EPS
Dividend History for Innoviva (NASDAQ:THRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Innoviva (NASDAQ:THRX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Innoviva (NASDAQ:THRX)
Latest Headlines for Innoviva (NASDAQ:THRX)
Innoviva (THRX) Chart for Wednesday, September, 20, 2017